6533b833fe1ef96bd129c1df

RESEARCH PRODUCT

Does the use of fibrin glue prevent seroma formation after axillary lymphadenectomy for breast cancer? A prospective randomized trial in 159 patients.

Salvatore VieniSalvatore FricanoCalogero CipollaGiuseppa GraceffaGaspare LicariMario Adelfio LatteriAdriana Torcivia

subject

Adultmedicine.medical_specialtymedicine.medical_treatmentseroma formationBreast NeoplasmsFibrin Tissue AdhesiveSuctionlaw.inventionbreast cancerBreast cancerPostoperative ComplicationsRandomized controlled triallawmedicineHumansIn patientProspective StudiesFibrin glueMastectomyAgedAged 80 and overbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseSurgeryfibrin glueSettore MED/18 - Chirurgia Generalesurgical procedures operativeSeromaOncologyAxillary LymphadenectomySeromaAxillaLymph Node ExcisionSurgeryFemaleTissue Adhesivesaxillary lymphadenectomybusinessQuadrantectomyMastectomy

description

Background Seroma formation frequently occurs in patients who have undergone axillary lymphadenectomy. The aim of the study was to evaluate the effect of fibrin glue in the prevention of seroma formation after axillary lymphadenectomy. Materials and Methods Hundred fifty-nine breast cancer patients about to undergo quadrantectomy or mastectomy plus axillary lymphadenectomy were enrolled in the study and randomized into two groups. Fibrin glue spray applied to the axillary fossa plus placement of closed suction drainage were used in 80 patients (group A); placement of closed suction drainage was only used in 79 patients (group B). Results Group A patients showed a slight advantage with regard to the mean duration of axillary drainage placement (4.5 ± 1.3 days in group A vs. 5.1 ± 1.6 days in group B) and number of seroma aspirations (6.3 ± 1.1 in group A vs. 6.7 ± 1.2 in group B). No statistically significant differences were observed between the two groups of patients regarding the mean volume of total axillary drainage and of total seroma volume. Conclusions The use of fibrin glue does not prevent seroma formation and does not reduce seroma magnitude and duration. The costs of the product involved do not justify its routine use in patients undergoing axillary dissection. J. Surg. Oncol. 2010; 101:600–603. © 2010 Wiley-Liss, Inc.

10.1002/jso.21531https://pubmed.ncbi.nlm.nih.gov/20461767